Management of antiphospholipid syndrome.

PubWeight™: 0.93‹?›

🔗 View Article (PMID 19559568)

Published in J Autoimmun on June 25, 2009

Authors

Josephine I Tuthill1, Munther A Khamashta

Author Affiliations

1: The Louise Coote Lupus Unit, St Thomas' Hospital, London, UK.

Articles by these authors

(truncated to the top 100)

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12

Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) (2003) 4.00

Systemic lupus erythematosus. Lancet (2007) 3.32

Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) (2007) 2.90

Antiphospholipid syndrome. Lancet (2010) 2.47

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest (2009) 2.11

Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol (2003) 1.99

Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol (2008) 1.88

Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) (2010) 1.83

A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum (2007) 1.82

Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol (2003) 1.76

British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum (2007) 1.74

Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood (2010) 1.67

Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum (2006) 1.56

GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford) (2013) 1.55

Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev (2009) 1.53

The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) (2009) 1.52

Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford) (2013) 1.46

N2010 adult-onset Still's disease complicated by hemophagocytic syndrome and catastrophic antiphospholipid syndrome resulting in four limb amputation. Isr Med Assoc J (2013) 1.43

Fluctuation of anti-endothelial cell antibody titers in " mixed connective tissue disease. Isr Med Assoc J (2012) 1.42

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev (2011) 1.27

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) (2011) 1.25

Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. Thromb Haemost (2012) 1.24

Management of the obstetric antiphospholipid syndrome. Arthritis Rheum (2004) 1.23

Oxidation of LDL and its clinical implication. Autoimmun Rev (2008) 1.22

Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation (2012) 1.20

Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol (2004) 1.17

Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol (2004) 1.16

Hughes syndrome crosses boundaries. Autoimmun Rev (2002) 1.14

Numerical scoring for the Classic BILAG index. Rheumatology (Oxford) (2009) 1.13

Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost (2005) 1.12

Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine (Baltimore) (2008) 1.10

Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med (2002) 1.10

Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS'). Ann Rheum Dis (2011) 1.09

Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) (2005) 1.05

Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis (2012) 1.02

Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res (2003) 0.98

Seronegative antiphospholipid syndrome. Rheumatology (Oxford) (2013) 0.98

Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum (2009) 0.96

Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol (2004) 0.96

Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum (2008) 0.94

Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. Arthritis Rheum (2008) 0.94

Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol (2006) 0.94

Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep (2008) 0.93

Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost (2013) 0.92

Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. J Rheumatol (2011) 0.92

Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol (2011) 0.90

B-cell-depleting therapy in systemic lupus erythematosus. Am J Med (2012) 0.90

Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des (2008) 0.90

Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev (2012) 0.89

The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev (2012) 0.86

Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis (2012) 0.86

Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review. J Neurol (2014) 0.86

Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood (2004) 0.86

Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol (2005) 0.86

Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus. Semin Arthritis Rheum (2002) 0.85

Central nervous system involvement in systemic lupus erythematosus: Overview on classification criteria. Autoimmun Rev (2012) 0.84

Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. Arthritis Care Res (Hoboken) (2014) 0.82

Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis (2012) 0.82

Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance. Thromb Haemost (2003) 0.82

Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med (2005) 0.81

[B-cell-depletion therapy in systemic autoinmune diseases. Recommendations for use in clinical practice]. Med Clin (Barc) (2010) 0.81

Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. Blood (2012) 0.80

Nonsteroidal anti-inflammatory drugs and reversible female infertility: is there a link? Drug Saf (2002) 0.80

The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally. Rheumatology (Oxford) (2012) 0.80

Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins. Clin Lab (2004) 0.80

Management of thrombosis in antiphospholipid syndrome and systemic lupus erythematosus in pregnancy. Ann N Y Acad Sci (2005) 0.80

Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res (Hoboken) (2012) 0.79

Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus. Ann Rheum Dis (2006) 0.79

B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J Autoimmun (2013) 0.79

Lupus and pregnancy: integrating clues from the bench and bedside. Eur J Clin Invest (2010) 0.79

Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum (2003) 0.79

Antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am (2007) 0.79

Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop? Curr Rheumatol Rep (2013) 0.78

The treatment of antiphospholipid syndrome: a harmonic contrast. Best Pract Res Clin Rheumatol (2007) 0.78

Management of refractory anti-phospholipid syndrome. Autoimmun Rev (2011) 0.78

Epidemiology of systemic lupus erythematosus at the change of the millennium: lessons from the Euro-Lupus and the LUMINA projects. Lupus (2006) 0.78

Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost (2012) 0.77

The DWEYS peptide in systemic lupus erythematosus. Trends Mol Med (2012) 0.77

The use of laboratory methods in differential diagnosis and treatment of SLE and antiphospholipid syndrome. Expert Rev Clin Immunol (2007) 0.77

Treatment of pregnancy loss in Hughes syndrome: a critical update. Autoimmun Rev (2002) 0.77

[Neurological manifestations of the antiphospholipid syndrome]. Med Clin (Barc) (2005) 0.76

Lack of association of antibodies to ribosomal P proteins with lupus membranous glomerulonephritis: comment on the article by Do Nascimento et al. Arthritis Rheum (2006) 0.76

Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy. Am J Obstet Gynecol (2003) 0.76

Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. J Rheumatol (2002) 0.76

New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. Curr Rheumatol Rep (2014) 0.76

Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol (2009) 0.76

The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus. Expert Rev Clin Immunol (2013) 0.76

Targeted therapy in antiphospholipid syndrome. Curr Opin Rheumatol (2014) 0.75

Postpartum spontaneous colonic perforation due to antiphospholipid syndrome. World J Gastroenterol (2009) 0.75

Antiphosphatidylserine/prothrombin antibodies in systemic lupus erythematosus. J Rheumatol (2013) 0.75

Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. Arthritis Rheum (2002) 0.75

How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood (2007) 0.75

Low-dose pulse cyclophosphamide in the treatment of neuropsychiatric lupus. Lupus (2003) 0.75

Intensity and duration of oral anticoagulation in antiphospholipid antibody associated thrombosis. J Rheumatol (2002) 0.75

Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome. Ann Rheum Dis (2011) 0.75

Connective tissue disease: Trial of SLE therapies in real-world settings. Nat Rev Rheumatol (2012) 0.75

Antiphospholipid antibodies and risk for recurrent vascular events. JAMA (2004) 0.75